Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.70 |
| ▸ | CASP3 | P42574 | 2/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 12/20 | 0.70 |
| ▸ | RAB9A | P51151 | 11/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.70 |
| ▸ | RELA | Q04206 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 5/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153407 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2CASP3SENP7SENP6NPC1 | |
| SCHEMBL2245275 | 0.89 | NPC1 (0.63) | SMN1; SMN2CASP3SENP7SENP6NPC1 | |
| SCHEMBL2244100 | 0.88 | NPC1 (0.70) | SMN1; SMN2CASP3SENP7SENP6NPC1 | |
| SCHEMBL29364223 | 0.88 | NPC1 (0.78) | SMN1; SMN2CASP3NPC1RAB9AKDM4E | |
| SCHEMBL2270976 | 0.88 | NPC1 (0.78) | SMN1; SMN2CASP3NPC1RAB9AKDM4E | |
| SCHEMBL12209706 | 0.84 | NPC1 (0.72) | SMN1; SMN2CASP3NPC1RAB9AKDM4E | |
| SCHEMBL1734841 | 0.83 | NPC1 (0.76) | SMN1; SMN2CASP3SENP7SENP6NPC1 | |
| SCHEMBL29622897 | 0.83 | NPC1 (0.76) | SMN1; SMN2CASP3SENP7SENP6NPC1 | |
| SCHEMBL29838123 | 0.83 | NPC1 (0.80) | SMN1; SMN2CASP3NPC1RAB9AKDM4E | |
| SCHEMBL12209714 | 0.83 | NPC1 (0.70) | SMN1; SMN2CASP3NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8330039-B2 | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2380208-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| WO-2010085664-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100180947-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| EP-1933834-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007042816-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | disclosed |
| EP-1483261-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 | SMN1; SMN2 3147/4885CASP3 332/4885SENP7 2533/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | SMN1; SMN2 4/4885CASP3 4141/4885SENP7 2647/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | SMN1; SMN2 4/4885CASP3 4141/4885SENP7 2647/4885 |
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | SMN1; SMN2 2389/4885CASP3 607/4885SENP7 1549/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | SMN1; SMN2 9/4885CASP3 2481/4885SENP7 4246/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | SMN1; SMN2 9/4885CASP3 2481/4885SENP7 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.